INTRODUCTION
Several genes are well validated as causes of a typical Parkinson disease phenotype. Although mutations in SNCA and LRRK2 cause autosomal dominant Parkinson disease, PARKIN, PINK1 and DJ1 mutations underlie autosomal recessive disease. However, known monogenic causes and genetic risk factors only partly explain the observed familial aggregation of Parkinson disease. Unsurprisingly, the application of new techniques such as next generation sequencing (NGS), genome-wide association studies (GWAS) and meta-analyses have allowed for the discovery of new genes and genetic risk factors for Parkinson disease and other movement disorders, such as dystonia, essential tremor and restless legs syndrome (RLS). In addition, clinicogenetic studies have been used to improve genotype-phenotype correlations and to reveal the earliest disease signs. Furthermore, there has been significant progress in the development of new disease models, particularly through the use of induced pluripotent stem (iPS) cell-derived neurons. Examples of these advances are given in this review.
Because disease-causing mutations usually change an encoded protein, NGS can be restricted to the coding part of the genome, the exome [1] .
Two independent studies utilized exome sequencing in a Swiss and an Austrian kindred to identify the same p.D620N (c.1858G>A) mutation in the vacuolar protein sorting 35 homolog (VPS35) gene as the cause of autosomal dominant Parkinson disease in these families [2 && ,3 && ]. This mutation was subsequently found in several additional families but is a rare cause of Parkinson disease, with a frequency lower than 0.1% [2 && ,3 && , [4] [5] [6] . The p.D620N mutation cosegregates with a phenotype indistinguishable from idiopathic Parkinson disease (iPD) and has incomplete, age-associated penetrance. This mutation seems to have arisen by recurrent mutational events [2 && ,6], and screening of the entire VPS35 coding region has not revealed any other variants with unequivocal pathogenicity [ in 2008 after genome-wide linkage analysis and sequencing of candidate genes [9] . Since then, additional families with mutations in FBOX7 have been described (reviewed in [10] ).
Of note, monogenic forms of Parkinson disease were initially assigned a 'PARK' designation using consecutive numbering, such as PARK1 for the first mapped and identified Parkinson disease gene SNCA. However, the current system has problems that are sources of confusion, perpetuate misinformation and misrepresent the system as a useful reference tool. These include erroneously assigned loci, duplicated loci, missing symbols and loci, unconfirmed loci, combining causative genes and risk factor genes in the same list, and discordance between phenotype and list assignment. For this reason, a substantial revision of the classification of inherited forms of parkinsonism is required [11] .
IDENTIFICATION OF GENETIC RISK FACTORS FOR PARKINSON DISEASE: ASSOCIATION STUDIES
GWAS have been a major advance in genetic research, enabling the assessment of genetic risk factors associated with complex diseases via largescale, population-based studies.
Several GWAS for Parkinson disease have been reported [12] [13] [14] [15] [16] [17] [18] [19] and three meta-analyses have been performed [20, 21 && ,22 && ]. All GWAS indicate a strong association to the SNCA gene and most studies also confirm an association with the MAPT gene ( Table 1) [12] [13] [14] [15] [16] 18, 19] . Early in 2011, the International Parkinson's Disease Genomics Consortium (IPDGC) performed a meta-analysis of datasets from five Parkinson disease GWAS across the United States and Europe in order to identify novel risk loci for Parkinson disease [22 && ]. The investigators identified 11 loci that surpassed the threshold for genome-wide significance. Six had been previously identified (MAPT, SNCA, HLA-DRB5, BST1, GAK and LRRK2), whereas five were novel (ACMSD, STK39, MCCC1/LAMP3, SYT11 and CCDC62/ HIP1R). A second meta-analysis by the IPDGC in collaboration with the Wellcome Trust Case Control Consortium 2 revealed another five Parkinson disease risk loci (PARK16, STX1B, FGF20, STBD1 and GPNMB) [20] . The third and most comprehensive meta-analysis included data from seven million polymorphisms originating either from GWAS datasets or from smaller scale Parkinson disease association studies and was supplemented by unpublished data [21 && ]. Many previously reported risk loci were confirmed and evidence for a new risk variant in the ITGA8 gene was found [21 && ]. The risk factors identified by these studies provide clues to the underlying molecular mechanisms involved and offer potential targets for novel treatments.
In addition to the GWAS, candidate gene association studies have also improved our knowledge of genetic risk factors. Variants in LRRK2 can cause monogenic Parkinson disease (e.g. p.G2019S) [23] or act as risk factors (e.g. p.G2385R) [24] . A large multicenter study systematically investigated the association of 121 exonic variants in LRRK2 with Parkinson disease in more than 15 
AGE-DEPENDENT PENETRANCE IN GENETIC PARKINSON DISEASE: AN OPPORTUNITY TO STUDY THE EARLY PHASES OF THIS DISEASE
The uptake of NGS and GWAS has resulted in a rapid expansion of our understanding of the genetics of Parkinson disease. However, there has often been a delay in the reporting of detailed genotypephenotype correlations. Recently, several studies were published that attempted to address this issue.
LRRK2 mutations: increasing risk for Parkinson disease
Mutations in LRRK2 are a well established cause of autosomal dominant Parkinson disease, with the most common mutation being the p.G2019S substitution. LRRK2 mutations have incomplete ageassociated penetrance, for example the penetrance Table 1 . Results of published genome-wide association studies in Parkinson disease Satake et al. [14] Simon-Sachez et al. [12] Edwards et al. [15] Hamza et al. [19] Do et al. [13] Spencer et al. [18] Saad et al. of the p.G2019S mutation is 28% at age 59 years, 51% at 69 years, and 74% at 79 years [28] . The age at onset seems to be at least partly influenced by variants in the MAPT gene [29] . The phenomenon of age-dependent penetrance provides an opportunity to study at-risk individuals, that is asymptomatic carriers of LRRK2 mutations, with the expectation that many will go on to develop Parkinson disease. These individuals may have the best prospects to benefit from neuroprotective agents developed in the future, based on the perception that substantial irreversible neuronal damage has not yet occurred in these individuals. In addition, studying these patients provides an opportunity to explore the earliest disease manifestations, and thus helps to better understand the pathophysiology and natural course of the disease.
A recent study compared the phenotype of probands with the p.G2019S mutation and their family members to patients with iPD and unrelated controls [30] . Although tremor was a more common presenting feature of LRRK2-Parkinson disease than iPD, the phenotypes were largely indistinguishable at the bedside. Nonmanifesting mutation carriers were also compared to related noncarriers, and a higher frequency of postural or action tremor was found in the nonmanifesting mutation carriers. However, the specificity of this sign as a predictor of future parkinsonism is likely to be low. Another study found evidence of olfactory dysfunction in nonmanifesting carriers of the p.G2019S mutation, supporting the notion that this is a premotor sign of Parkinson disease [31] . Additionally, sensitive gait analysis was used to demonstrate subtle gait abnormalities among asymptomatic carriers of the p.G2019S mutation [32] .
Glucocerebrosidase mutations in Parkinson disease: risk variant or dominant causal gene?
Although monogenic forms of Parkinson disease are caused by rare mutations, genetic risk factors are usually common variants (Fig. 1) . Mutations in the glucocerebrosidase (GBA) gene, causing Gaucher disease when both alleles are mutated, have an intermediate frequency in Parkinson disease patients (6.7% in a large European study) [33] . The phenotype associated with heterozygous GBA mutations in Parkinson disease may be indistinguishable from iPD in terms of severity, however, it seems that GBAParkinson disease patients may be at higher risk of developing cognitive impairment [34] .
A French study found the penetrance of GBA mutations to be 7.6, 13.7, 21.4 and 29.7% at 50, 60, Satake et al. [14] Simon-Sachez et al. [12] Edwards et al. [15] Hamza et al. [19] Do et al. [13] Spencer et al. [18] Saad et al. [16] LOC401725 ( Genome-wide association study results were combined with preexisting data.
70, and 80 years, respectively [35 & ]. The relatively high penetrance of Parkinson disease in GBA carriers suggested that GBA is in fact a dominant causal gene with reduced penetrance, rather than just a riskconferring gene. These findings should be taken into consideration when counseling relatives of patients with Gaucher disease or GBA-associated Parkinson disease.
FUNCTIONAL MODELING OF PARKINSON DISEASE: INDUCED PLURIPOTENT STEM CELLS AS A NEW TOOL
Functional studies of Parkinson disease-causing mutations have been hindered by lack of access to affected human dopaminergic neurons. The use of iPS cell-derived neurons (Fig. 2) provides a unique opportunity to overcome this difficulty.
Several studies have utilized iPS cell-derived neurons as cellular models in idiopathic and genetic Parkinson disease including SNCA, LRRK2 and PINK1 mutations. For example, increased production of SNCA was demonstrated in iPS cellderived midbrain neurons from an SNCA triplication carrier [36] . Dopaminergic neurons with missense or nonsense mutations in PINK1 were shown to have reduced PINK1-mediated recruitment of Parkin to mitochondria [37] . Expression of wildtype PINK1 rescued the effect of mutant PINK1 on Parkin translocation, further confirming the relevance of PINK1/Parkin pathway in human neurons [37] . Dopaminergic neurons with the p.G2019S mutation in LRRK2 showed enhanced sensitivity to stress, a finding which could correlate with an early Parkinson disease phenotype [38] . In another study, a reduction in the number of neurites and neurite arborization as well as an accumulation of autophagic vacuoles was found in iPS-derived dopaminergic neurons from LRRK2 carriers and iPD patients [39 & ]. These studies have effectively replicated molecular mechanisms known to be important in Parkinson disease. In addition, iPS cell-derived neurons have also been used to elucidate the molecular link between Gaucher disease and Parkinson disease [40 && ]. It was demonstrated that functional loss of Gaucher disease-linked glucocerebrosidase enzyme (GCase) in primary cultures or human iPS neurons impairs lysosomal protein degradation, causing accumulation of SNCA and resulting in neurotoxicity via aggregation-dependent mechanisms [40 && ]. It was also shown that SNCA inhibits the lysosomal activity of normal GCase in neurons and in the iPD brain. Based on these findings, a selfpropagating and 'bidirectional pathogenic loop' model was proposed. In this model, impaired activity of GCase (e.g. due to a GBA mutation) results in lysosomal dysfunction followed by accumulation and aggregation of SNCA. The accumulated SNCA then blocks vesicle transport between the endoplasmic reticulum and golgi apparatus, which is the chief trafficking route for GCase to reach the lysosome. This leads to a reduction in GCase in the lysosome, amplifying the pathological process by causing further impairment of SNCA degradation, fuelling a feed-forward loop [41] . Presumably, at some point, SNCA reaches a critical level and becomes associated with disease. This model raises the possibility of a new therapeutic strategy for Parkinson disease, that is, raising GCase levels in sporadic Parkinson disease patients [41] .
ADVANCES IN OTHER MOVEMENT DISORDERS
Key advances in the genetics of paroxysmal dyskinesia, essential tremor and RLS have recently been made through the use of NGS and GWAS. There is an emerging recognition of the important role of genetics in other movement disorders, such as Tourette syndrome, and this is covered in detail elsewhere [42 && ].
PRRT2 mutations as a cause of paroxysmal kinesigenic dyskinesia and benign familial infantile seizures: two faces of the same coin
Paroxysmal kinesigenic dyskinesia (PKD; DYT10) is an episodic dyskinesia of brief duration triggered by movement. Infantile convulsions and choreoathetosis (ICCA) syndrome is characterized by the coinheritance of benign familial infantile seizures (BFIS) and PKD. Using NGS, several studies independently identified mutations in the PRRT2 gene as the major cause of PKD and ICCA syndrome [43] [44] [45] 46 && ]. Furthermore, PRRT2 mutations have now been identified in pure BFIS families [47, 48] . An unprecedented number of studies have been published regarding PRRT2 mutations in a relatively short period of time. These reports have demonstrated that mutations in the same gene can cause two conditions (BFIS and PKD), which at first glance appear to be clinically distinct [49] .
Genome-wide association studies: further clues to the genetic contribution to essential tremor
The first GWAS in essential tremor found an association of essential tremor risk with two single nucleotide polymorphisms (SNPs) (rs9652490 and rs11856808) located in an intron of the leucine-rich repeat and Ig domain containing 1 (LINGO1) gene [50] . Recently, a meta-analysis compared the results from 11 studies and supported a relationship between rs11856808 and the risk for essential tremor, whereas rs9652490 was only associated with familial essential tremor [51 & ]. It is important to note that LINGO1 rs9652490 may be in linkage disequilibrium with an as yet uncovered functional variant, which may be located in LINGO1 or in another gene [52] . Another GWAS found an association of essential tremor with variants in the glutamate transporter SLC1A2 [53] .
Restless legs syndrome: additional risk variants have been identified
RLS is characterized by high familial aggregation suggesting a genetic component. Despite intensive efforts, no monogenic cause has been detected to date. However, major advances have been achieved through the identification of genetic risk factors by a GWAS (BTBD9, MEIS1, MAP2K5/SKOR1) and candidate region analysis (PTPRD) [54, 55] . These results were confirmed in several studies [56, 57] . A recent GWAS has identified two additional RLS susceptibility loci within an intergenic region on chromosome 2p14 and a locus on 16q12.1 [58 && ]. Opportunities now exist to study the functionality of the RLS risk susceptibility loci and the molecular pathways involved [59] . An illustrative example includes a study reporting that the MEIS1 risk variant influences iron metabolism [60] , adding to a growing body of evidence that iron dysregulation contributes to the pathogenesis of many movement disorders [61] .
CONCLUSION
The increasing application of new technologies such as NGS and GWAS has allowed for a clearer picture of the heritability of Parkinson disease and other movement disorders. The genetic factors involved can be placed on a curve of effect size versus allele frequency (Fig. 1) [62] . Detailed analysis of the specific phenotypes associated with genetic forms of Parkinson disease is imperative, given that establishment of endophenotypes within the Parkinson disease spectrum may enable a better understanding of the pathogenesis and aid the development of targeted therapeutic interventions [63] . Monogenic forms of Parkinson disease account for only a small proportion of Parkinson disease cases. However, the finding of new genetic factors is vital, given that research into the molecular mechanisms underlying these mutations may provide insights into the pathophysiology of iPD. With the emergence of new disease models such as iPS cell-derived neurons, we have now greatly enhanced our capability to study these mechanisms.
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